Browse all articles

Home Get the app

Head to head Published Apr 20, 2026

Alpha-GPC vs CDP-Choline (Citicoline)

For daily focus and memory, pick Citicoline (250–500 mg/day). For a one-off workout power boost, Alpha-GPC (≈600 mg pre-session) has limited acute data—but weigh a cohort signal of higher long-term stroke risk if used chronically, especially in older adults.

Evidence: promising 8 criteria 16 sources

The verdict

Citicoline wins for routine cognitive support and overall safety/regulatory backing in healthy adults, with multiple RCTs and favorable PK. Alpha-GPC may suit occasional pre-workout use or targeted short trials, but its long-term benefit–risk profile is less clear and an observational cohort suggests increased stroke risk in older users. Choose Citicoline for most daily needs; reserve Alpha-GPC for situational performance if you're low cardiovascular risk and monitored. 681234

The contenders

Two ways to approach the same goal

Option A

Alpha-GPC (choline alphoscerate)

Common forms include AlphaSize, 99% or 50% titrations

Standardization

Typically 50% or 99% Alpha-GPC; ~40–41% choline by weight

Forms

Capsules, powder (often hygroscopic)

Typical dosage

300–600 mg once or twice daily; 600 mg 60–90 min pre-workout studied acutely

Strengths

  • High choline density; fast cholinergic support
  • Small RCTs suggest acute power/GH response around workouts
  • Signals of benefit in cognitive impairment in some trials/meta-analysis

Trade-offs

  • Observational signal of increased long-term stroke risk in older adults
  • Hygroscopic; purity/titration vary (50% vs 99%)
  • Evidence for healthy adults is limited vs citicoline

Safety

Generally well-tolerated short-term; GI upset, heartburn, insomnia/headache reported. Large Korean cohort linked chronic use with higher 10-yr stroke risk; discuss with a clinician, especially if at vascular risk.

Option B

CDP-Choline (Citicoline)

Common branded form: Cognizin

Standardization

≥98% citicoline (EFSA spec for novel food); often sold as Cognizin 250–500 mg

Forms

Capsules, powder; beverages in some markets

Typical dosage

250–500 mg/day for cognition; clinical/medical uses 500–1,000+ mg/day under supervision

Strengths

  • Human PK shows near-complete absorption; raises plasma choline and uridine (via cytidine)
  • Multiple RCTs show benefits to attention and episodic memory in healthy/older adults
  • Robust regulatory safety opinions up to 500–1,000 mg/day

Trade-offs

  • Some acute-stroke meta-analyses show no benefit on hard outcomes
  • Mild side effects (headache, insomnia, GI) possible
  • Lower choline density than Alpha-GPC (~18%)

Safety

EFSA considers citicoline safe at 500 mg/day in supplements and up to 1,000 mg/day in FSMPs; generally well-tolerated in RCTs. Caution with stimulating effects later in day; theoretical interactions with dopaminergic/cholinergic drugs—consult a clinician.

Head-to-head

How they compare, criterion by criterion

Efficacy for everyday focus/attention in healthy adults

Winner: B · CDP-Choline (Citicoline)

Importance: high

Citicoline improved attention/impulsivity in RCTs (adolescents; middle-aged women) and enhanced episodic memory in older adults; Alpha-GPC lacks comparable RCTs in healthy cohorts. 691011

Memory support in age-associated decline

Winner: B · CDP-Choline (Citicoline)

Importance: high

Citicoline (500 mg/day, 12 weeks) improved episodic and composite memory in AAMI; Alpha-GPC shows benefit mainly in impairment/dementia and a recent small MCI RCT, but overall evidence in healthy aging is weaker. 9212

Acute performance (power/explosiveness)

Winner: A · Alpha-GPC (choline alphoscerate)

Importance: medium

Single 600 mg Alpha-GPC dose 90 min pre-exercise increased bench-press peak force and GH vs placebo in a crossover trial; no comparable citicoline data. 1

Onset/time-to-effect

Winner: A · Alpha-GPC (choline alphoscerate)

Importance: medium

Alpha-GPC shows acute effects within 1–2 h in exercise study; citicoline cognitive RCTs show benefits after 4–12 weeks. 1910

Safety/tolerability (chronic use)

Winner: B · CDP-Choline (Citicoline)

Importance: high

Citicoline has EFSA safety opinion up to 500–1,000 mg/day with good tolerability; a large cohort linked chronic Alpha-GPC use with higher 10-yr stroke risk. 734

Bioavailability and mechanistic breadth

Winner: B · CDP-Choline (Citicoline)

Importance: medium

Citicoline is near-completely absorbed and elevates plasma choline and uridine (uridine supports membrane/phospholipid synthesis); Alpha-GPC is choline-dense (~41% choline) but lacks uridine provision. 5138

Standardization/quality consistency

Winner: B · CDP-Choline (Citicoline)

Importance: medium

Citicoline has ≥98% spec in EFSA novel food approval and widely used branded Cognizin; Alpha-GPC often sold at 50% or 99% titrations—label clarity varies. 7

Cost/value per effective daily dose (U.S.)

Winner: Tie · Either option

Importance: low

Indicative retail: Citicoline (Cognizin) ≈$0.30–$0.45 per 250 mg; Alpha-GPC powder ≈$1/gram (≈$0.30 per 300 mg). Prices vary by brand and form. 1415

Which should you choose

By goal and use case

Daily focus/attention or mental clarity (students, knowledge work)

Choose B · CDP-Choline (Citicoline)

Multiple RCTs in healthy cohorts show attention benefits at 250–500 mg/day; good tolerability and standardized supply. 1011

Episodic memory support in healthy older adults (AAMI)

Choose B · CDP-Choline (Citicoline)

12-week RCT showed improvements in episodic and composite memory at 500 mg/day. 9

Pre-workout power or explosive effort (occasional use)

Choose A · Alpha-GPC (choline alphoscerate)

600 mg ~90 min pre-lift increased peak force and GH acutely; consider as situational aid rather than chronic use. 1

Cognitive impairment or vascular cognitive issues (with clinician)

Choose Tie · Either option

Alpha-GPC shows signals in impairment (meta-analysis; MCI RCT), while citicoline has mixed data in stroke; selection should be clinician-guided. 21216

Stacking with uridine/DHA or racetams

Choose B · CDP-Choline (Citicoline)

Citicoline supplies choline plus cytidine→uridine, complementing phospholipid and synaptic membrane synthesis; widely used as choline base in stacks. 513

Safety considerations

  • Citicoline: EFSA deems safe at 500 mg/day for supplements and up to 1,000 mg/day in FSMPs; RCTs report mild AEs (headache, GI, insomnia) in a minority. Take earlier in the day if stimulating. 7910 - Alpha-GPC: Generally well-tolerated short-term; GI upset/heartburn, headache/insomnia reported. A large Korean cohort (n≈12M, age≥50) associated chronic α-GPC prescriptions with increased 10-yr stroke risk (aHR≈1.43–1.46; dose-response). Discuss long-term use with a clinician if you have vascular risk factors. 34 - Drug interactions: Both are cholinergic; theoretical interactions with anticholinergics/anticholinesterases; citicoline may interact with dopaminergic regimens—consult a clinician. 7 - General: Avoid late-evening dosing if sleep-sensitive. Pregnant/breastfeeding: insufficient data—seek medical advice.

Frequently asked

Common questions

Which should I try first for day-to-day concentration?

Citicoline 250–500 mg/day has multiple RCTs in healthy cohorts and strong safety/regulatory backing. 10117

Is Alpha-GPC safe for long-term daily use?

Short-term use is usually well-tolerated, but a large cohort linked chronic α-GPC use to higher 10-yr stroke risk—discuss with your clinician if considering long-term use. 34

Can I take them together?

Usually unnecessary; both supply choline. If stacking for experiments, start low, monitor for cholinergic side effects, and avoid late dosing. Consult a clinician if on cholinergic/dopaminergic meds. 7

Best timing?

Citicoline: morning or early day. Alpha-GPC: ~60–90 min before training for acute effects; earlier in day if using for cognition to avoid insomnia. 17

Which is better value?

Costs are similar per practical dose; check titration (Alpha-GPC 50% vs 99%) and per-cap mg. Compare cost per 250–500 mg citicoline vs 300–600 mg Alpha-GPC. 1415

Related

Read each variant on its own

Standalone evidence guides and systematic reviews for the supplements being compared here.

Sources

  1. 1. Acute supplementation with alpha-GPC augments GH response and peak force (2008) RCT (crossover) ↑
  2. 2. Choline alphoscerate for adult-onset cognitive dysfunctions: systematic review/meta-analysis (2023) Systematic review/meta-analysis ↑
  3. 3. Association of α-GPC with 10-year stroke risk (JAMA Netw Open) (2021) Cohort study ↑
  4. 4. Association of α-GPC with stroke risk – full text (PMC) (2021) Cohort full text ↑
  5. 5. Effect of oral CDP-choline on plasma choline and uridine in humans (2000) Human PK ↑
  6. 6. Citicoline enhances frontal lobe bioenergetics (31P-MRS) (2008) Imaging study ↑
  7. 7. EFSA opinion: citicoline as a novel food ingredient (safety) (2013) Regulatory safety opinion ↑
  8. 8. L-α-GPC review noting ~41% choline and BBB passage (2024) Review ↑
  9. 9. Citicoline and memory in healthy older adults (12-wk RCT) (2021) RCT ↑
  10. 10. Citicoline improves attention in healthy adult women (RCT) (2012) RCT (report) ↑
  11. 11. Citicoline improves attention/motor speed in adolescents (RCT) (2015) RCT ↑
  12. 12. α-GPC for amnestic MCI (12-wk RCT) (2024) RCT ↑
  13. 13. Citicoline bioavailability review (NMJ summary) (2015) Review (summarizing human PK) ↑
  14. 14. Alpha-GPC 99% powder price example (60 g ≈ $60) (2025) Retail snapshot ↑
  15. 15. Cognizin 250 mg price examples (30–150 caps) (2025) Retail snapshot ↑
  16. 16. Early citicoline in acute stroke: meta-analysis (2016) Meta-analysis ↑

Want personalized recommendations?

Show me what works for me